cellectar biosciences is developing phospholipid drug conjugates (pdcs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. cellectar's pdc platform is based on the company's proprietary phospholipid ether analogs. these novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. cellectar's pdc pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. the company's lead therapeutic pdc, clr 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. clr 131 has been designated as an orphan drug by the us fda and is currently being evaluated in a phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a phase 2 clinical study to assess efficacy in a range of b-cell malignancies. the company is also developing proprietary pdcs for targeted delivery of chemotherapeutics and has several preclinical stage p
Company profile
Ticker
CLRB
Exchange
Website
CEO
James Caruso
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
COMMON HORIZONS INC, NOVELOS THERAPEUTICS, INC.
SEC CIK
Corporate docs
Subsidiaries
Cellectar, Inc. ...
CLRB stock data
Latest filings (excl ownership)
8-K
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update
27 Mar 24
10-K
2023 FY
Annual report
27 Mar 24
8-K
Other Events
2 Feb 24
8-K
Other Events
25 Jan 24
8-K
Other Events
9 Jan 24
8-K
Other Events
29 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Reports Preliminary Financial Results for Third Quarter 2023 and Provides a Corporate Update
2 Nov 23
EFFECT
Notice of effectiveness
31 Oct 23
Latest ownership filings
SC 13G/A
Rosalind Advisors, Inc.
14 Feb 24
SC 13G
Nantahala Capital Management, LLC
14 Feb 24
SC 13G/A
Lincoln Park Capital Fund, LLC
14 Feb 24
SC 13G/A
LYTTON LAURENCE W
14 Feb 24
SC 13G/A
HIRSCHMAN ORIN
7 Feb 24
SC 13G
ADAR1 Partners, LP
31 Jan 24
4
Darrell Shane Lea
12 Dec 23
4
Chad J Kolean
12 Dec 23
4
Andrei Shustov
12 Dec 23
4
Jarrod Longcor
12 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 18.99 mm | 18.99 mm | 18.99 mm | 18.99 mm | 18.99 mm | 18.99 mm |
Cash burn (monthly) | (no burn) | (no burn) | 3.14 mm | 2.82 mm | 2.69 mm | 2.52 mm |
Cash used (since last report) | n/a | n/a | 20.99 mm | 18.86 mm | 17.99 mm | 16.83 mm |
Cash remaining | n/a | n/a | -2.01 mm | 122.81 k | 994.62 k | 2.15 mm |
Runway (months of cash) | n/a | n/a | -0.6 | 0.0 | 0.4 | 0.9 |
Institutional ownership, Q3 2023
17.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 23 |
Opened positions | 4 |
Closed positions | 5 |
Increased positions | 6 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 3.80 bn |
Total shares | 5.55 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
North Sound Trading | 2.16 mm | $4.50 mm |
Rosalind Advisors | 986.29 k | $0.00 |
Lincoln Park Capital Fund | 937.59 k | $1.71 mm |
AIGH Capital Management | 677.51 k | $1.79 bn |
Worth Venture Partners | 279.12 k | $736.89 mm |
Vanguard | 175.88 k | $464.33 mm |
Acuta Capital Partners | 121.30 k | $320.23 mm |
Geode Capital Management | 62.85 k | $165.98 mm |
BLK Blackrock | 57.04 k | $150.59 mm |
Renaissance Technologies | 21.69 k | $57.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Dec 23 | Andrei Shustov | Common Stock | Grant | Acquire A | No | No | 0 | 47,856 | 0.00 | 55,037.7 |
28 Jun 23 | Asher Chanan-Khan | Stock option Common Stock | Grant | Acquire A | No | No | 1.85 | 25,000 | 46.25 k | 40,600 |
28 Jun 23 | Loren Stefan | Stock option Common Stock | Grant | Acquire A | No | No | 1.85 | 25,000 | 46.25 k | 47,885 |
28 Jun 23 | Driscoll Frederick W | Stock option Common Stock | Grant | Acquire A | No | No | 1.85 | 25,000 | 46.25 k | 47,650 |
28 Jun 23 | Neis John | Stock option Common Stock | Grant | Acquire A | No | No | 1.85 | 25,000 | 46.25 k | 47,887 |
News
Roth MKM Maintains Buy on Cellectar Biosciences, Raises Price Target to $28
28 Mar 24
Oppenheimer Reiterates Outperform on Cellectar Biosciences, Raises Price Target to $12
28 Mar 24
Cellectar Biosciences Q4 EPS $(0.40) Beats $(0.59) Estimate
27 Mar 24
Earnings Scheduled For March 27, 2024
27 Mar 24
Earnings Preview For Cellectar Biosciences
26 Mar 24
Press releases
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update
27 Mar 24
Cellectar Biosciences to Present at the 36th Annual Roth Conference
14 Mar 24
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer
4 Mar 24
Thinking about buying stock in TOP Financial Group, Macy's, MicroCloud Hologram, Cellectar Biosciences, or New York Community Bancorp?
9 Feb 24
Thinking about buying stock in Plug Power, Confluent, Cellectar Biosciences, Bakkt Holdings, or Digital Turbine?
8 Feb 24